What's Going On With Novo Nordisk Stock On Friday?

Core Viewpoint - Novo Nordisk A/S is experiencing stock price fluctuations due to lower-than-expected fiscal 2026 guidance and concerns regarding competition from unapproved products [1][2]. Group 1: Financial Guidance - Novo Nordisk expects adjusted sales growth for 2026 to be between -5% to -13% at constant exchange rates, excluding revenue from the reversal of 340B provisions [2]. Group 2: Legal and Regulatory Actions - Novo Nordisk has announced plans to take legal and regulatory action against Hims & Hers for unlawfully mass-marketing an unapproved and untested semaglutide pill [3][4]. - The FDA has indicated it will take swift action against companies marketing illegal copycat drugs, emphasizing the inability to verify the quality, safety, or effectiveness of non-approved drugs [5]. Group 3: Stock Performance - As of the latest publication, Novo Nordisk's stock is up 8.32% at $46.96, trading 8.6% above its 52-week low [6].